ABNewswire - Press Release Distribution Service

Sunday, April 27, 2025

Adult-onset Still Disease Market Expected to rise by 2034, Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., expected to drive market expansion | DelveInsight

Adult-onset Still Disease market growth 2034

The Adult-onset Still Disease market growth is driven by factors like increase in the prevalence of Adult-onset Still Disease, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Adult-onset Still Disease market report also offers comprehensive insights into the Adult-onset Still Disease market size, share, Adult-onset Still Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Adult-onset Still Disease market size growth forward.

Some of the key highlights from the Adult-onset Still Disease Market Insights Report:

As per DelveInsight analysis, the Adult-onset Still Disease market is anticipated to witness growth at a considerable CAGR
Several key pharmaceutical companies, including Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., and others, are developing novel products to improve the Adult-onset Still Disease treatment outlook.
DelveInsight’s epidemiology model estimates that in the US, there were approximately 2,325 diagnosed prevalent cases of AOSD in 2023. This number is expected to increase during the forecast period (2024-2034), driven by greater awareness, improved screening, and advancements in genetic testing.
Among the EU4 countries and the UK, Germany had the highest number of diagnosed prevalent cases of AOSD, with about 691 cases in 2023. France followed with approximately 560 cases, and the UK had nearly 550 cases.
According to DelveInsight, in 2023, there were approximately 7,464 diagnosed cases of Adult-Onset Still's Disease (AOSD) across the 7 Major Markets (7MM). The United States accounted for about 31% of these cases, while the EU4 and the UK collectively represented around 37%, and Japan accounted for nearly 32%.
The AOSD market is expected to grow steadily, with a projected compound annual growth rate (CAGR) of 5% from 2024 to 2034. This growth is driven by the introduction of new therapies, such as Tadekinig Alfa, along with increased awareness, improved diagnosis, and advancements in treatment options.
FDA-approved drugs like Canakinumab (Novartis), Anakinra (Swedish Orphan Biopharma), and Tocilizumab (Roche) for AOSD indicate significant market potential, reflecting the growing recognition of AOSD as a distinct therapeutic target.

Strategise your business goals by understanding market dynamics @ Adult-onset Still Disease Market Landscape

Adult-onset Still Disease Overview

Adult-Onset Still's Disease (AOSD) is a rare systemic inflammatory condition with an unknown cause, leading to significant morbidity. It typically presents with a combination of symptoms such as high fever, a characteristic rash, prolonged joint pain, and systemic issues like sore throat, splenomegaly, hepatomegaly, and lymphadenopathy. While the exact causes are unclear, AOSD may be triggered by environmental factors or infections in individuals genetically predisposed to the condition. Risk factors include a history of autoimmune diseases and age, as AOSD primarily affects adults between their 20s and 40s. The complexity of its diagnosis and the variability of symptoms make treatment and management challenging, underscoring the need for increased awareness and further research.

Do you know the treatment paradigms for different countries? Download our Adult-onset Still Disease Market Sample Report

Adult-onset Still Disease Epidemiology Segmentation

DelveInsight’s Adult-onset Still Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Adult-onset Still Disease historical patient pools and forecasted Adult-onset Still Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Adult-onset Still Disease Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Adult-onset Still Disease Prevalence
Age-Specific Adult-onset Still Disease Prevalence
Gender-Specific Adult-onset Still Disease Prevalence
Diagnosed and Treatable Cases of Adult-onset Still Disease

Visit for more @ Adult-onset Still Disease Epidemiological Insights

Adult-onset Still Disease Market Outlook

Adult-Onset Still’s Disease (AOSD) is a rare autoinflammatory condition triggered by the innate immune system, causing symptoms like fever, rash, arthritis, sore throat, and liver or spleen involvement. Due to its rarity and lack of large studies, diagnosing AOSD is difficult, and treatment often relies on smaller case reports and clinical experience.

Initial therapy typically involves NSAIDs and corticosteroids, but many patients require escalation to disease-modifying antirheumatic drugs (DMARDs) or biologics if symptoms persist. Biologics targeting inflammatory pathways—such as IL-1 receptor antagonists (e.g., KINERET and ILARIS) and TNF inhibitors—have become important options. In Japan, ACTEMRA (tocilizumab) is approved for cases resistant to other treatments.

New therapies, like Tadekinig alfa (an IL-18 binding protein), have shown early promise but lack sufficient recent data to be included in treatment forecasts. Overall, the AOSD treatment landscape continues to evolve, with research focused on expanding and refining therapeutic strategies.

Adult-onset Still Disease Marketed Drugs

ILARIS (canakinumab): NOVARTIS
KINERET (anakinra): Swedish Orphan Biovitrum
ACTEMRA (tocilizumab): Genentech (ROCHE)

Adult-onset Still Disease Emerging Drugs

Tadekinig Alfa: AB2 Bio

Adult-onset Still Disease Key Companies

Cerecor
Roche
Swedish Orphan Biovitrum
Novartis
Swedish Orphan Biovitrum
AB2 Bio Ltd.
And others

For more information, visit Adult-onset Still Disease Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Adult-onset Still Disease Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Adult-onset Still Disease, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Adult-onset Still Disease epidemiology in the 7MM
Adult-onset Still Disease marketed and emerging therapies
Adult-onset Still Disease companies
Adult-onset Still Disease market drivers and barriers

Table of Contents:

1 Adult-onset Still Disease Market Key Comprehensive Insights

2 Adult-onset Still Disease Market Report Introduction

3 Competitive Intelligence Analysis for Adult-onset Still Disease

4 Adult-onset Still Disease Market Analysis Overview at a Glance

5 Executive Summary of Adult-onset Still Disease

6 Adult-onset Still Disease Epidemiology and Market Methodology

7 Adult-onset Still Disease Epidemiology and Patient Population

8 Adult-onset Still Disease Patient Journey

9 Adult-onset Still Disease Treatment Algorithm, Adult-onset Still Disease Current Treatment, and Medical Practices

10 Key Endpoints in Adult-onset Still Disease Clinical Trials

11 Adult-onset Still Disease Marketed Therapies

12 Adult-onset Still Disease Emerging Therapies

13 Adult-onset Still Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Adult-onset Still Disease

16 Adult-onset Still Disease Market Key Opinion Leaders Reviews

18 Adult-onset Still Disease Market Drivers

19 Adult-onset Still Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Adult-onset Still Disease Epidemiology 2034

DelveInsight's "Adult-onset Still Disease - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Adult-onset Still Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Adult-onset Still Disease Pipeline 2024

"Adult-onset Still Disease Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Adult-onset Still Disease market. A detailed picture of the Adult-onset Still Disease pipeline landscape is provided, which includes the disease overview and Adult-onset Still Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Chronic Hand Eczema Market Expected to rise by 2034, LEO Pharma, Japan Tobacco, Asana Biosciences, expected to drive market expansion | DelveInsight

Chronic Hand Eczema market growth 2034

The Chronic Hand Eczema market growth is driven by factors like increase in the prevalence of Chronic Hand Eczema, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Chronic Hand Eczema market report also offers comprehensive insights into the Chronic Hand Eczema market size, share, Chronic Hand Eczema epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Hand Eczema market size growth forward.

Some of the key highlights from the Chronic Hand Eczema Market Insights Report:

Several key pharmaceutical companies, including LEO Pharma, Japan Tobacco, Asana Biosciences, and others, are developing novel products to improve the Chronic Hand Eczema treatment outlook.
According to DelveInsight, the chronic hand eczema market is expected to undergo significant changes during the forecast period (2024-2034), driven by advancements in medical research and technology, better diagnostic tools, and the introduction of new therapies.
In September, 2024, LEO Pharma Inc. made two important announcements. First, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for delgocitinib cream 20 mg/g (2%) as a treatment for adults with moderate to severe Chronic Hand Eczema (CHE), particularly for those who have not responded to or cannot use topical corticosteroids.
In September 2024, LEO Pharma A/S announced that the European Commission (EC) granted marketing authorization for Anzupgo® (delgocitinib) cream. This approval provides a new treatment option for adult patients with moderate to severe CHE in Europe, particularly where traditional corticosteroid treatments have proven ineffective. These announcements underscore LEO Pharma's continued leadership in dermatological care and represent a significant step forward in improving treatment options for chronic hand eczema patients.
In 2023, the total market size for chronic hand eczema in the United States was approximately USD 431 million. Among the EU4 countries and the UK, Germany had the largest market size at around USD 71 million, followed by France and the UK with approximately USD 46 million and USD 45 million, respectively.
In the EU4 countries and the UK, Germany had the highest number of chronic hand eczema cases, with nearly 493,000, followed by France and the UK with approximately 321,000 and 317,000 cases, respectively. In the US, nearly 1 million cases were diagnosed, and this number is projected to increase by 2034 due to environmental factors like weather conditions, and lifestyle factors such as stress and poor skincare habits.
Chronic hand eczema affects females more than males, primarily due to exposure to irritants from household and skincare products. In 2023, there were around 1 million females and 993,000 males with the condition in the US.
In the UK, cases of chronic hand eczema in 2023 were distributed across age groups as follows: approximately 52,000 cases in those aged 20-29 years, 98,000 in those aged 30-49 years, 29,000 in those aged 50-69 years, and 26,000 in those aged 70 and above.
In Japan, chronic hand eczema represented approximately 15% of global cases in 2023. Among various subtypes, irritant contact eczema was the most prevalent, accounting for around 27% of cases, while fingertip eczema had the lowest prevalence at about 4%. These cases are expected to increase by 2034, driven by modern lifestyle factors such as high stress, poor dietary habits, and sedentary behavior, which worsen inflammatory conditions like eczema in Japan.
Companies involved in chronic hand eczema treatment development, including Regeneron, Sanofi, Stiefel Laboratories, and Asana Biosciences, are exploring potential treatments that could be launched during the forecast period (2024-2034).

Strategise your business goals by understanding market dynamics @ Chronic Hand Eczema Market Landscape

Chronic Hand Eczema Overview

Chronic hand eczema is a common inflammatory skin condition marked by dry, red, itchy, and often painful patches on the hands. It can occur in cycles of flare-ups and remissions or persist continuously. Causes include genetic factors, environmental triggers like irritants and allergens, frequent handwashing, and stress. The condition can severely impact daily life, leading to both physical discomfort and emotional distress.

Diagnosis is made through a thorough medical history, physical skin examination, and sometimes additional tests. Doctors assess symptoms, skin appearance, and possible triggers related to lifestyle or work. Patch testing may be performed to identify allergens, and other skin conditions like psoriasis, fungal infections, or contact dermatitis may be ruled out. Accurate diagnosis helps in developing a personalized treatment plan for better management of the disease.

Do you know the treatment paradigms for different countries? Download our Chronic Hand Eczema Market Sample Report

Chronic Hand Eczema Epidemiology Segmentation

DelveInsight’s Chronic Hand Eczema market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Hand Eczema historical patient pools and forecasted Chronic Hand Eczema patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Hand Eczema Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Chronic Hand Eczema Prevalence
Age-Specific Chronic Hand Eczema Prevalence
Gender-Specific Chronic Hand Eczema Prevalence
Diagnosed and Treatable Cases of Chronic Hand Eczema

Visit for more @ Chronic Hand Eczema Epidemiological Insights

Chronic Hand Eczema Market Insights

Several types of medications are commonly used to manage chronic hand eczema. Topical corticosteroids are the first-line treatment, helping to reduce inflammation, itching, and swelling during flare-ups, though they are generally used short-term to avoid side effects like skin thinning. Topical calcineurin inhibitors (such as tacrolimus and pimecrolimus) are effective alternatives, especially for sensitive areas like the hands and face, as they work by calming the skin’s immune response.

Emollients and moisturizers are crucial for daily care, helping to repair the skin barrier, lock in moisture, and prevent irritation and flare-ups. Topical immunomodulators like crisaborole are also used to control inflammation, particularly when corticosteroids or calcineurin inhibitors are unsuitable or ineffective. These treatments are often combined for a more effective, tailored approach to managing the condition.

Chronic Hand Eczema Market Outlook

Current management of chronic hand eczema primarily relies on topical treatments, including corticosteroids, calcineurin inhibitors, and moisturizers, to alleviate symptoms, control inflammation, and repair the skin barrier. For more severe cases, systemic options like oral medications or biologic therapies may be considered. The chronic hand eczema treatment market is steadily advancing, driven by improved medical understanding, the introduction of new therapies, shifting patient expectations, increased awareness among healthcare providers and patients, and the impact of environmental and lifestyle changes.

Chronic Hand Eczema Marketed Drugs

TOCTINO (alitretinoin): Basilea Pharmaceutica/ Stiefel Laboratories

Chronic Hand Eczema Emerging Drugs

ARQ-252: Arcutis Biotherapeutics
Delgocitinib: LEO Pharma/Japan Tobacco

Chronic Hand Eczema Key Companies

LEO Pharma
Japan Tobacco
Asana Biosciences
And others

For more information, visit Chronic Hand Eczema Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Chronic Hand Eczema Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Chronic Hand Eczema, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Chronic Hand Eczema epidemiology in the 7MM
Chronic Hand Eczema marketed and emerging therapies
Chronic Hand Eczema companies
Chronic Hand Eczema market drivers and barriers

Table of Contents:

1 Chronic Hand Eczema Market Key Comprehensive Insights

2 Chronic Hand Eczema Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Hand Eczema

4 Chronic Hand Eczema Market Analysis Overview at a Glance

5 Executive Summary of Chronic Hand Eczema

6 Chronic Hand Eczema Epidemiology and Market Methodology

7 Chronic Hand Eczema Epidemiology and Patient Population

8 Chronic Hand Eczema Patient Journey

9 Chronic Hand Eczema Treatment Algorithm, Chronic Hand Eczema Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Hand Eczema Clinical Trials

11 Chronic Hand Eczema Marketed Therapies

12 Chronic Hand Eczema Emerging Therapies

13 Chronic Hand Eczema: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Hand Eczema

16 Chronic Hand Eczema Market Key Opinion Leaders Reviews

18 Chronic Hand Eczema Market Drivers

19 Chronic Hand Eczema Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Hand Eczema Epidemiology 2034

DelveInsight's "Chronic Hand Eczema - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Hand Eczema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Hand Eczema Pipeline 2024

"Chronic Hand Eczema Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Hand Eczema market. A detailed picture of the Chronic Hand Eczema pipeline landscape is provided, which includes the disease overview and Chronic Hand Eczema treatment guidelines.

Small Cell Lung Cancer Market Expected to rise, 2034 | Ipsen Biopharmaceuticals, BMS, Xcovery Holding Company, EpicentRx, Amgen, expected to rise

Small Cell Lung Cancer market growth 2034

The Small Cell Lung Cancer market growth is driven by factors like increase in the prevalence of Small Cell Lung Cancer, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, share, Small Cell Lung Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Small Cell Lung Cancer market size growth forward.

Some of the key highlights from the Small Cell Lung Cancer Market Insights Report:

As per DelveInsight analysis, the Small Cell Lung Cancer market is anticipated to witness growth at a considerable CAGR
Several key pharmaceutical companies, including Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, Amgen, and others, are developing novel products to improve the Small Cell Lung Cancer treatment outlook.
In December 2024, Xcovery Holdings, Inc. announced that the U.S. Food and Drug Administration has approved ensartinib (Ensacove) for treating patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval represents a significant step forward in offering a new first-line treatment option for patients with ALK-positive NSCLC.
In September 2024, AbbVie filed a biologics license application (BLA) with the FDA, requesting accelerated approval for telisotuzumab vedotin (Teliso-V) to treat patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) that shows c-Met protein overexpression.
According to DelveInsight, the Small Cell Lung Cancer (SCLC) market is expected to experience significant growth between 2024 and 2034, driven by the introduction of new therapies and a rise in the number of cases. Lung cancer affects over 200,000 people annually in the United States and an estimated 2.3 million globally. Small Cell Lung Cancer accounts for 10% to 15% of lung cancer cases. The 5-year relative survival rate for individuals with SCLC in the U.S. is 8% for women and 6% for men.
Treatments for SCLC include IMFINZI (durvalumab) for extensive-stage SCLC and ZEPZELCA (lurbinectedin) for metastatic cases. Approximately 25% of individuals with limited-stage SCLC can be cured with timely chemotherapy and radiation therapy. The long-standing treatment approach involves platinum etoposide, with topotecan serving as a second-line option for those who respond well to platinum-based therapies. Although topotecan has a response rate of around 20%, its survival benefit is limited compared to the best supportive care.
The number and effectiveness of SCLC treatments remain far behind those for non-Small Cell Lung Cancer, which has seen significant advancements in targetable therapies and better responses to immunotherapy. Recently, immunotherapy has shown promise for SCLC, but challenges regarding toxicity and efficacy remain, and additional treatment options are needed to address the disease's various subtypes. Key companies such as Ipsen Biopharmaceuticals (Onivyde), Bristol-Myers Squibb (BMS-986012), Xcovery Holding Company (Vorolanib), EpicentRx (RRx-001), and Amgen (AMG 757) are advancing their lead candidates through various stages of clinical development.
In 2023, it is estimated that there will be approximately 238,340 new cases of lung cancer in the United States, with 117,550 cases in men and 120,790 cases in women. The statistics typically include both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). SCLC accounts for about 10% to 15% of all lung cancers, while NSCLC makes up approximately 80% to 85%.
In the U.S., Small Cell Lung Cancer is slightly more common in women (14%) than in men (13%). The risk of developing lung cancer increases with age, and both men and women are most likely to be diagnosed with Small Cell Lung Cancer between the ages of 75 and 79.
In the UK, around 15% to 20% of all lung cancer diagnoses are Small Cell Lung Cancer, which is primarily caused by smoking. This type of cancer tends to spread early in its progression.

Strategise your business goals by understanding market dynamics @ Small Cell Lung Cancer Market Landscape

Small Cell Lung Cancer Overview

Small Cell Lung Cancer (SCLC) is a highly aggressive form of lung cancer characterized by the rapid and uncontrolled growth of cells within the lungs, often leading to tumor development and metastasis to other parts of the body. Smoking is the primary risk factor, with almost all cases occurring in individuals who currently smoke or have a history of smoking. Early stages of the disease typically present no noticeable symptoms, and when symptoms do appear, they can vary widely among patients.

To diagnose lung cancer, doctors usually recommend imaging tests like CT, PET, or MRI scans to identify any lung abnormalities. A mucus sample may also be analyzed for cancer cells. If cancer is suspected, a biopsy — involving either a needle insertion or a small surgical procedure — is performed to collect lung tissue for examination. Bronchoscopy is another common technique used to view the lungs directly and obtain tissue samples.

Do you know the treatment paradigms for different countries? Download our Small Cell Lung Cancer Market Sample Report

Small Cell Lung Cancer Epidemiology Segmentation

DelveInsight’s Small Cell Lung Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Small Cell Lung Cancer historical patient pools and forecasted Small Cell Lung Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Small Cell Lung Cancer Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Small Cell Lung Cancer Prevalence
Age-Specific Small Cell Lung Cancer Prevalence
Gender-Specific Small Cell Lung Cancer Prevalence
Diagnosed and Treatable Cases of Small Cell Lung Cancer

Visit for more @ Small Cell Lung Cancer Epidemiological Insights

Small Cell Lung Cancer Treatment Market

Over the past 30 years, progress in improving survival rates for Small Cell Lung Cancer (SCLC) patients has been minimal, largely due to the cancer's aggressive growth, early metastasis, and resistance to chemotherapy. Treatment decisions are based on the cancer stage, patient health, and personal preferences, and may involve surgery, chemotherapy, radiation, or immunotherapy. Standard chemotherapy typically includes Etoposide or Irinotecan with a platinum-based drug like Cisplatin or Carboplatin. Limited-stage SCLC is treated with combined chemotherapy and radiation, while extensive-stage disease often involves chemotherapy, sometimes paired with immunotherapy.

Recent advancements have introduced immune checkpoint inhibitors like nivolumab, pembrolizumab, atezolizumab, and durvalumab for first-line therapy. Lurbinectedin is now approved for second-line treatment, and trilaciclib helps prevent chemotherapy-induced myelosuppression. However, in 2021, approvals for nivolumab and pembrolizumab in later-stage treatment were withdrawn, though they remain in use alongside other therapies.

Research is ongoing to develop new treatments, with hopes that biomarker-driven approaches will significantly improve outcomes, much like in non-Small Cell Lung Cancer (NSCLC). Companies like Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, and Amgen are actively advancing new therapies through clinical trials.

Small Cell Lung Cancer Marketed Drugs

ZEPZELCA (lurbinectedin): PharmaMar and Jazz Pharmaceuticals
IMFINZI (durvalumab): AstraZeneca

Small Cell Lung Cancer Emerging Drugs

RRx-001: EpicentRx

Small Cell Lung Cancer Key Companies

Bristol-Myers Squibb
Merck
AstraZeneca
PharmaMar
EpicentRx
And others

For more information, visit Small Cell Lung Cancer Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Small Cell Lung Cancer Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Small Cell Lung Cancer, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Small Cell Lung Cancer epidemiology in the 7MM
Small Cell Lung Cancer marketed and emerging therapies
Small Cell Lung Cancer companies
Small Cell Lung Cancer market drivers and barriers

Table of Contents:

1 Small Cell Lung Cancer Market Key Comprehensive Insights

2 Small Cell Lung Cancer Market Report Introduction

3 Competitive Intelligence Analysis for Small Cell Lung Cancer

4 Small Cell Lung Cancer Market Analysis Overview at a Glance

5 Executive Summary of Small Cell Lung Cancer

6 Small Cell Lung Cancer Epidemiology and Market Methodology

7 Small Cell Lung Cancer Epidemiology and Patient Population

8 Small Cell Lung Cancer Patient Journey

9 Small Cell Lung Cancer Treatment Algorithm, Small Cell Lung Cancer Current Treatment, and Medical Practices

10 Key Endpoints in Small Cell Lung Cancer Clinical Trials

11 Small Cell Lung Cancer Marketed Therapies

12 Small Cell Lung Cancer Emerging Therapies

13 Small Cell Lung Cancer: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Small Cell Lung Cancer

16 Small Cell Lung Cancer Market Key Opinion Leaders Reviews

18 Small Cell Lung Cancer Market Drivers

19 Small Cell Lung Cancer Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Small Cell Lung Cancer Epidemiology 2034

DelveInsight's "Small Cell Lung Cancer - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Small Cell Lung Cancer Pipeline 2024

"Small Cell Lung Cancer Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Small Cell Lung Cancer market. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Small Cell Lung Cancer treatment guidelines.

Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected Drive Market

Atypical hemolytic uremic syndrome market growth 2034

The atypical hemolytic uremic syndrome market growth is driven by factors like increase in the prevalence of Atypical Hemolytic Uremic Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The atypical hemolytic uremic syndrome market growth is driven by factors like increase in the prevalence of Atypical Hemolytic Uremic Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Atypical Hemolytic Uremic Syndrome market report also offers comprehensive insights into the Atypical Hemolytic Uremic Syndrome market size, share, Atypical Hemolytic Uremic Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Atypical Hemolytic Uremic Syndrome market size growth forward.

Some of the key highlights from the Atypical Hemolytic Uremic Syndrome Market Insights Report:

As per DelveInsight analysis, the Atypical Hemolytic Uremic Syndrome market is anticipated to witness growth at a considerable CAGR
Several key pharmaceutical companies, including Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others, are developing novel products to improve the Atypical Hemolytic Uremic Syndrome treatment outlook.
In April 2024, Hoffmann-La Roche revealed the results of a Phase III, multicenter, single-arm study assessing the efficacy, safety, pharmacokinetics, and pharmacodynamics of Crovalimab in pediatric patients with atypical hemolytic uremic syndrome (aHUS).
In February 2024, Alexion Pharmaceuticals, Inc. announced the results of a prospective, single-arm, multicenter study evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in complement inhibitor treatment-naïve pediatric and adult patients with aHUS in China.
In 2023, the United States had the largest market share for Atypical Hemolytic Uremic Syndrome (aHUS) among the 7MM, and this market is expected to grow with a compound annual growth rate (CAGR) of approximately 4% by 2034.
There are two types of HUS: Typical HUS, caused by pathogens like E. coli, and atypical HUS, which is often linked to genetic mutations, but can also be triggered by illnesses or other unknown causes. Most aHUS cases are genetic, although some can be acquired through autoantibodies or idiopathic causes. The condition can become chronic, leading to complications such as hypertension and kidney failure.
The disease is related to gene mutations and triggering events, like pregnancy, infections, cancers, and certain medications. The clinical manifestations of aHUS can involve various organ systems, including renal, hematologic, respiratory, ocular, skin, CNS, cardiovascular, and GI systems.
Diagnosis includes a complete blood count (CBC) to measure red blood cell and platelet counts, and an estimated glomerular filtration rate (eGFR) to assess kidney function.
In 2023, there were nearly 4,800 diagnosed cases of aHUS in the 7MM, with the majority of cases being in adults and adolescents (around 4,000 cases) compared to pediatric cases (approximately 700 cases).
Currently, only eculizumab and ravulizumab are approved for treatment, both developed by Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021. Iptacopan (LNP023), an oral drug by Novartis, is in Phase III trials and could become a preferred treatment due to its convenient oral administration. It is expected to generate over USD 500 million by 2034.

Strategise your business goals by understanding market dynamics @ Atypical Hemolytic Uremic Syndrome Market Landscape

Atypical Hemolytic Uremic Syndrome Overview

Atypical Hemolytic Uremic Syndrome (aHUS) is a rare disorder marked by the destruction of red blood cells (causing hemolytic anemia), a reduced platelet count (thrombocytopenia), and acute kidney failure (uremia), which compromises the kidneys' ability to eliminate waste. In aHUS, red blood cells break apart as they move through clots in small blood vessels, and if the body can't produce new cells fast enough, anemia develops. This process can severely damage the kidneys, with about half of affected individuals progressing to end-stage renal disease (ESRD).

Diagnosing aHUS is often difficult, particularly in cases without a clear family history. It is primarily based on the combination of hemolytic anemia, low platelet levels, and signs of kidney impairment.

Treatment strategies focus on managing kidney injury and associated complications. Severe anemia may require transfusions of packed red blood cells, while platelet transfusions are reserved for extreme cases. Careful management of fluids and electrolytes is critical, nephrotoxic drugs should be avoided, and blood pressure must be controlled. In instances of kidney failure, renal replacement therapy may be needed. Targeted therapies such as plasma exchange and complement inhibitors, including eculizumab and ravulizumab, address the root cause of the disease.

Do you know the treatment paradigms for different countries? Download our Atypical Hemolytic Uremic Syndrome Market Sample Report

Atypical Hemolytic Uremic Syndrome Epidemiology Insights

DelveInsight’s epidemiology model estimates that there were approximately 5K diagnosed cases of aHUS across the 7MM in 2023, with this number expected to rise throughout the forecast period.
The United States had the highest number of aHUS cases, with nearly 3,500 cases reported in 2023, and this figure is projected to increase by 2034.
Among the 7MM, adolescents and adults made up about 80% of the diagnosed cases in 2023.

Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation

DelveInsight’s Atypical Hemolytic Uremic Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Atypical Hemolytic Uremic Syndrome historical patient pools and forecasted Atypical Hemolytic Uremic Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Atypical Hemolytic Uremic Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Atypical Hemolytic Uremic Syndrome Prevalence
Age-Specific Atypical Hemolytic Uremic Syndrome Prevalence
Gender-Specific Atypical Hemolytic Uremic Syndrome Prevalence
Diagnosed and Treatable Cases of Atypical Hemolytic Uremic Syndrome

Visit for more @ Atypical Hemolytic Uremic Syndrome Epidemiological Insights

Atypical Hemolytic Uremic Syndrome Market Insights:

Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Atypical Hemolytic Uremic Syndrome (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.
According to DelveInsight's patient-based forecasting model, the total aHUS market size in the 7MM was USD 1.3 billion in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.
Among emerging therapies for aHUS, Novartis’ iptacopan and Roche’s crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Atypical Hemolytic Uremic Syndrome Market Outlook

The introduction of complement C5 inhibition has significantly enhanced patient outcomes and quality of life (QoL) in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). The available complement C5 inhibitors in the 7MM are SOLIRIS (eculizumab) and ULTOMIRIS (ravulizumab), both products of Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021.

Switching patients from eculizumab to ravulizumab has proven to be an effective treatment strategy. This transition reduces the frequency of dosing, resulting in lower treatment-related costs and improved patient QoL.

Despite their proven safety and effectiveness, the high cost of eculizumab and ravulizumab limits their accessibility in the treatment landscape. As a result, there is a significant need for more effective pharmacological options, especially for managing the more severe and disabling stages of aHUS.

While several promising therapies are under investigation for aHUS, it is too early to confirm which will enter the market during the forecast period (2024–2034). However, it is clear that the future of this market holds promise. These new treatments are expected to bring substantial improvements to the aHUS treatment landscape in the coming years, driven by increasing global healthcare spending.

Atypical Hemolytic Uremic Syndrome Marketed Drugs

ULTOMIRIS (ravulizumab): Alexion Pharmaceuticals
SOLIRIS (eculizumab): Alexion Pharmaceuticals

Atypical Hemolytic Uremic Syndrome Emerging Drugs

Crovalimab (RG6107; SKY59): Hoffmann-La Roche/Chugai Pharmaceutical
FABHALTA (iptacopan): Novartis Pharmaceuticals

Atypical Hemolytic Uremic Syndrome Key Companies

Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others

Scope of the Atypical Hemolytic Uremic Syndrome Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Atypical Hemolytic Uremic Syndrome, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM
Atypical Hemolytic Uremic Syndrome marketed and emerging therapies
Atypical Hemolytic Uremic Syndrome companies
Atypical Hemolytic Uremic Syndrome market drivers and barriers

Table of Contents:

1 Atypical Hemolytic Uremic Syndrome Market Key Comprehensive Insights

2 Atypical Hemolytic Uremic Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Atypical Hemolytic Uremic Syndrome

4 Atypical Hemolytic Uremic Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Atypical Hemolytic Uremic Syndrome

6 Atypical Hemolytic Uremic Syndrome Epidemiology and Market Methodology

7 Atypical Hemolytic Uremic Syndrome Epidemiology and Patient Population

8 Atypical Hemolytic Uremic Syndrome Patient Journey

9 Atypical Hemolytic Uremic Syndrome Treatment Algorithm, Atypical Hemolytic Uremic Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Atypical Hemolytic Uremic Syndrome Clinical Trials

11 Atypical Hemolytic Uremic Syndrome Marketed Therapies

12 Atypical Hemolytic Uremic Syndrome Emerging Therapies

13 Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Atypical Hemolytic Uremic Syndrome

16 Atypical Hemolytic Uremic Syndrome Market Key Opinion Leaders Reviews

18 Atypical Hemolytic Uremic Syndrome Market Drivers

19 Atypical Hemolytic Uremic Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Atypical Hemolytic Uremic Syndrome Epidemiology 2034

DelveInsight's "Atypical Hemolytic Uremic Syndrome - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Atypical Hemolytic Uremic Syndrome Pipeline 2024

"Atypical Hemolytic Uremic Syndrome Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Atypical Hemolytic Uremic Syndrome market. A detailed picture of the Atypical Hemolytic Uremic Syndrome pipeline landscape is provided, which includes the disease overview and Atypical Hemolytic Uremic Syndrome treatment guidelines.

Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected to Drive Market

Some of the key highlights from the Atypical Hemolytic Uremic Syndrome Market Insights Report:

As per DelveInsight analysis, the Atypical Hemolytic Uremic Syndrome market is anticipated to witness growth at a considerable CAGR
Several key pharmaceutical companies, including Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others, are developing novel products to improve the Atypical Hemolytic Uremic Syndrome treatment outlook.
In April 2024, Hoffmann-La Roche revealed the results of a Phase III, multicenter, single-arm study assessing the efficacy, safety, pharmacokinetics, and pharmacodynamics of Crovalimab in pediatric patients with atypical hemolytic uremic syndrome (aHUS).
In February 2024, Alexion Pharmaceuticals, Inc. announced the results of a prospective, single-arm, multicenter study evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in complement inhibitor treatment-naïve pediatric and adult patients with aHUS in China.
In 2023, the United States had the largest market share for Atypical Hemolytic Uremic Syndrome (aHUS) among the 7MM, and this market is expected to grow with a compound annual growth rate (CAGR) of approximately 4% by 2034.
There are two types of HUS: Typical HUS, caused by pathogens like E. coli, and atypical HUS, which is often linked to genetic mutations, but can also be triggered by illnesses or other unknown causes. Most aHUS cases are genetic, although some can be acquired through autoantibodies or idiopathic causes. The condition can become chronic, leading to complications such as hypertension and kidney failure.
The disease is related to gene mutations and triggering events, like pregnancy, infections, cancers, and certain medications. The clinical manifestations of aHUS can involve various organ systems, including renal, hematologic, respiratory, ocular, skin, CNS, cardiovascular, and GI systems.
Diagnosis includes a complete blood count (CBC) to measure red blood cell and platelet counts, and an estimated glomerular filtration rate (eGFR) to assess kidney function.
In 2023, there were nearly 4,800 diagnosed cases of aHUS in the 7MM, with the majority of cases being in adults and adolescents (around 4,000 cases) compared to pediatric cases (approximately 700 cases).
Currently, only eculizumab and ravulizumab are approved for treatment, both developed by Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021. Iptacopan (LNP023), an oral drug by Novartis, is in Phase III trials and could become a preferred treatment due to its convenient oral administration. It is expected to generate over USD 500 million by 2034.

Strategise your business goals by understanding market dynamics @ Atypical Hemolytic Uremic Syndrome Market Landscape

Atypical Hemolytic Uremic Syndrome Overview

Do you know the treatment paradigms for different countries? Download our Atypical Hemolytic Uremic Syndrome Market Sample Report

Atypical Hemolytic Uremic Syndrome Epidemiology Insights

DelveInsight’s epidemiology model estimates that there were approximately 5K diagnosed cases of aHUS across the 7MM in 2023, with this number expected to rise throughout the forecast period.
The United States had the highest number of aHUS cases, with nearly 3,500 cases reported in 2023, and this figure is projected to increase by 2034.
Among the 7MM, adolescents and adults made up about 80% of the diagnosed cases in 2023.

Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation

Atypical Hemolytic Uremic Syndrome Prevalence
Age-Specific Atypical Hemolytic Uremic Syndrome Prevalence
Gender-Specific Atypical Hemolytic Uremic Syndrome Prevalence
Diagnosed and Treatable Cases of Atypical Hemolytic Uremic Syndrome

Visit for more @ Atypical Hemolytic Uremic Syndrome Epidemiological Insights

Atypical Hemolytic Uremic Syndrome Market Insights:

Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Atypical Hemolytic Uremic Syndrome (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.
According to DelveInsight's patient-based forecasting model, the total aHUS market size in the 7MM was USD 1.3 billion in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.
Among emerging therapies for aHUS, Novartis’ iptacopan and Roche’s crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Atypical Hemolytic Uremic Syndrome Market Outlook

Atypical Hemolytic Uremic Syndrome Marketed Drugs

ULTOMIRIS (ravulizumab): Alexion Pharmaceuticals
SOLIRIS (eculizumab): Alexion Pharmaceuticals

Atypical Hemolytic Uremic Syndrome Emerging Drugs

Crovalimab (RG6107; SKY59): Hoffmann-La Roche/Chugai Pharmaceutical
FABHALTA (iptacopan): Novartis Pharmaceuticals

Atypical Hemolytic Uremic Syndrome Key Companies

Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others

For more information, visit Atypical Hemolytic Uremic Syndrome Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Atypical Hemolytic Uremic Syndrome Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Atypical Hemolytic Uremic Syndrome, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM
Atypical Hemolytic Uremic Syndrome marketed and emerging therapies
Atypical Hemolytic Uremic Syndrome companies
Atypical Hemolytic Uremic Syndrome market drivers and barriers

Table of Contents:

1Atypical Hemolytic Uremic Syndrome Market Key Comprehensive Insights

2Atypical Hemolytic Uremic Syndrome Market Report Introduction

3Competitive Intelligence Analysis for Atypical Hemolytic Uremic Syndrome

4Atypical Hemolytic Uremic Syndrome Market Analysis Overview at a Glance

5Executive Summary of Atypical Hemolytic Uremic Syndrome

6Atypical Hemolytic Uremic Syndrome Epidemiology and Market Methodology

7Atypical Hemolytic Uremic Syndrome Epidemiology and Patient Population

8Atypical Hemolytic Uremic Syndrome Patient Journey

9Atypical Hemolytic Uremic Syndrome Treatment Algorithm, Atypical Hemolytic Uremic Syndrome Current Treatment, and Medical Practices

10Key Endpoints in Atypical Hemolytic Uremic Syndrome Clinical Trials

11Atypical Hemolytic Uremic Syndrome Marketed Therapies

12Atypical Hemolytic Uremic Syndrome Emerging Therapies

13Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis

14Attribute analysis

15Access and Reimbursement Overview of Atypical Hemolytic Uremic Syndrome

16Atypical Hemolytic Uremic Syndrome Market Key Opinion Leaders Reviews

18Atypical Hemolytic Uremic Syndrome Market Drivers

19Atypical Hemolytic Uremic Syndrome Market Barriers

20SWOT Analysis

21Disclaimer

22DelveInsight Capabilities

23About DelveInsight

Related Reports:

Atypical Hemolytic Uremic Syndrome Epidemiology 2034

Atypical Hemolytic Uremic Syndrome Pipeline 2024

Saturday, April 26, 2025

Chronic Kidney Disease Market Poised for Rapid Growth Amid FDA Drug Approvals | DelveInsight

The chronic kidney disease (CKD) treatment market is witnessing robust expansion across the 7MM. This upward trajectory is primarily fueled by increasing disease prevalence, growing aging populations, rising diabetes and hypertension cases, and the emergence of innovative therapies from key chronic kidney disease players including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Vifor Pharma, Otsuka Pharmaceutical, Reata Pharmaceuticals, Akebia Therapeutics, and Kyowa Kirin, among others.

DelveInsight's "Chronic Kidney Disease Market Insight, Epidemiology, and Market Forecast - 2034" report provides comprehensive insights into chronic kidney disease, including historical and forecasted epidemiology, current treatment paradigms, and emerging therapies across the 7MM (United States, EU4, United Kingdom, and Japan).

According to the report, the market size of chronic kidney disease across the 7MM was approximately USD 4.6 billion in 2023, and is projected to grow steadily through 2034. The United States emerged as the largest contributor, accounting for nearly USD 2.5 billion of the total market, significantly outpacing other key regions such as the EU4, the UK, and Japan. Within Europe, Germany held the leading position and is expected to maintain its dominance by 2034, followed closely by the UK. While Japan also captured a considerable share, the overall market landscape is being shaped by rising prevalence, better diagnostic rates, and the adoption of advanced treatment approaches across major geographies.

Download the chronic kidney disease market report to understand which factors are driving the CKD therapeutic market @ Chronic Kidney Disease Market Trends.

According to DelveInsight's epidemiological analysis, the estimated total number of chronic kidney disease prevalent cases diagnosed in the 7MM was nearly 82 million in 2023, and this number is expected to increase significantly over the next decade. The US accounted for the highest total diagnosed prevalent cases of chronic kidney disease in 2023, with approximately 4 million cases. Further, stage 3 CKD represents the largest patient population segment in the 7MM.

Gender disparities in CKD prevalence and progression are becoming increasingly apparent, with women showing higher prevalence in early stages. Furthermore, age-specific data shows the highest prevalence among individuals aged 65 and older. These differential progression patterns highlight the need for gender- and age-specific approaches to CKD management and intervention.

Diabetes and hypertension remain the leading causes of CKD, while the prevalence increases substantially with age, with individuals over 65 years showing markedly higher rates compared to younger populations. Additionally, the increasing recognition of non-traditional risk factors, including obesity, environmental exposures, and certain medications, is reshaping our understanding of CKD epidemiology.

The chronic renal failure therapeutics landscape has evolved substantially in recent years, moving beyond traditional approaches focused solely on slowing disease progression to novel therapies targeting specific pathways. SGLT2 inhibitors, including FARXIGA (dapagliflozin) and INVOKANA (canagliflozin), have revolutionized renal disease management by demonstrating significant renoprotective benefits beyond glycemic control, substantially reducing the risk of kidney failure and cardiovascular events in CKD patients. The approval of KERENDIA (finerenone), a non-steroidal mineralocorticoid receptor antagonist, has further expanded treatment options by addressing inflammation and fibrosis pathways in diabetic kidney disease.

For renal anemia, the market has witnessed significant advancements with the approval of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, such as VAFSEO (Akebia Therapeutics) and EVRENZO (Astellas), which provide alternatives to traditional erythropoiesis-stimulating agents. These therapies offer improved convenience with oral administration and potentially reduced cardiovascular risks compared to injectable options. Additionally, KORSUVA (Cara Therapeutics) has addressed the significant burden of Uremic Pruritus (CKD-aP), substantially improving the quality of life for affected patients on hemodialysis.

According to DelveInsight's analysis, the renal treatment pipeline is robust, with several therapies in various development stages targeting different aspects of renal disease progression and complications. Notable candidates include Ocedurenone (KBP Biosciences), a nonsteroidal mineralocorticoid receptor antagonist being investigated for the treatment of resistant hypertension in patients with chronic kidney disease; Sparsentan (Travere Therapeutics), a dual endothelin and angiotensin receptor antagonist showing promise in IgA nephropathy and focal segmental glomerulosclerosis; and atrasentan (Chinook Therapeutics), an endothelin A receptor antagonist demonstrating potential in proteinuric kidney diseases.

Cell and gene therapies are also emerging as potential transformative approaches, with candidates like FCR001 (Talaris Therapeutics) being investigated for inducing immune tolerance in kidney transplant recipients. Additionally, several bispecific antibodies targeting inflammatory pathways involved in CKD progression are advancing through early clinical trials, potentially offering new mechanisms to address kidney inflammation and fibrosis.

Unlock which chronic kidney disease emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Chronic Kidney Disease Market Insights.

The chronic renal disease treatment landscape has seen significant advancements in early 2025, marked by key regulatory milestones and expanded therapeutic options.

In March 2025, the FDA expanded the approval of Furoscix (furosemide injection, scPharmaceuticals, Inc.) to include the treatment of edema in adult CKD patients, including those with nephrotic syndrome, with availability expected by April 2025.

Additionally, in January 2025, Semaglutide (Novo Nordisk) received FDA approval for a new indication to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD, further enhancing patient care.

Unicycive Therapeutics announced in November 2024 that the FDA has accepted its New Drug Application for Oxylanthanum Carbonate (OLC), targeting hyperphosphatemia in CKD patients on dialysis, with a PDUFA action date set for June 28, 2025. These developments underscore a rapidly evolving CKD market, offering new hope and improved outcomes for patients.

Discover evolving trends in the chronic kidney disease treatment landscape @ Chronic Kidney Disease Recent Developments.

Despite these advancements, significant challenges persist in the CKD treatment landscape. Early diagnosis remains elusive, with many patients identified only after substantial kidney damage has occurred. Additionally, the complex, multifactorial nature of renal diseases often requires combination therapies, creating concerns about polypharmacy, drug interactions, and economic burden. DelveInsight's analysis emphasizes the need for biomarker-driven, personalized treatment approaches and more effective strategies for early intervention to address these unmet needs.

Looking ahead, the chronic kidney disease market is poised for substantial transformation, with multiple late-stage therapies expected to gain approval in the coming years. Combination regimens leveraging complementary mechanisms of action are likely to become standard practice, offering more comprehensive kidney protection. Additionally, the integration of artificial intelligence in predictive modeling and treatment selection promises to enhance personalized care, potentially revolutionizing CKD management by enabling earlier intervention in high-risk populations and optimizing therapy selection based on individual patient characteristics and disease subtypes.

Table of Contents

1. Key Insights

2. Report Introduction

3. CKD Market Overview at a Glance

4. CKD Epidemiology and Market Forecast Methodology

5. Key Events

6. CKD Executive Summary

7. Disease Background and Overview of Chronic Kidney Disease (CKD)

8. CKDEpidemiology and Patient Population

9. CKD Patient Journey

10. CKD Marketed Drugs

11. CKD Emerging Drugs

12. CKD: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. CKD Unmet needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

Related Reports

Chronic Kidney Disease Pipeline Insight

Chronic Kidney Disease Pipeline Insight provides comprehensive insights about the CKD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the CKD companies, including AstraZeneca (LON: AZN), Eli Lilly and Company (NYSE: LLY), Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta (ASX: 1AD), Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics (NASDAQ: DMAC), Roche (SWX: ROG), MC2 Therapeutics, Allena Pharmaceuticals (NASDAQ: ALNA), Regulus Therapeutics (NASDAQ: RGLS), UnicoCell Biomed (TPE: 6794), and Regeneron Pharmaceuticals (NASDAQ: REGN), among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Bullous Keratopathy Market Poised for Robust Growth at an 11.5% CAGR Over the Coming Decade | DelveInsight

The bullous keratopathy treatment market is projected to experience substantial growth over the coming decade, driven by an aging population, increasing prevalence of cataract surgeries, glaucoma procedures, and novel pharmaceutical interventions by key bullous keratopathy players such as Aurion Biotechnologies, Emmecell, Trefoil Therapeutics, and Cellusion, among others.

DelveInsight's "Bullous Keratopathy Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of bullous keratopathy, historical and forecasted epidemiology, as well as the bullous keratopathy market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The report provides detailed insights into current treatment practices, bullous keratopathy emerging therapies, and market dynamics from 2020 to 2034, offering a comprehensive assessment of this evolving therapeutic landscape. This analysis serves as a crucial resource for stakeholders seeking to understand market potential and identify strategic opportunities in the bullous keratopathy treatment market.

According to DelveInsight's market assessment, the bullous keratopathy market size in the 7MM was valued at approximately USD 14 million in 2023 and is projected to grow at a robust CAGR of 11.5% during the forecast period (2024-2034). The US currently dominates the market, followed by the EU4 and UK regions, with Japan representing a significant growth opportunity due to its aging population and high prevalence of cataract surgeries. This market expansion reflects increasing disease awareness, improved diagnostic capabilities, and the anticipated launch of novel therapeutic interventions addressing the substantial unmet needs in bullous keratopathy management.

Download the bullous keratopathy market report to understand which factors are driving the bullous keratopathy therapeutic market @ Bullous Keratopathy Market Trends.

The report provides comprehensive epidemiological insights, revealing that approximately 200K diagnosed prevalent cases of bullous keratopathy were recorded across the 7MM in 2023, with the US accounting for the largest share at 41% of total cases. According to DelveInsight's analysis, the prevalence is expected to increase steadily through 2034, primarily due to demographic shifts toward an aging population and the rising volume of cataract surgeries, intraocular lens implantations, and other invasive ocular procedures that can damage corneal endothelial cells.

The current bullous keratopathy treatment landscape primarily relies on corneal transplantation techniques, particularly endothelial keratoplasty (EK) procedures, including Descemet's stripping automated endothelial keratoplasty (DSAEK) and Descemet's membrane endothelial keratoplasty (DMEK). While these surgical interventions can effectively restore vision, they face significant challenges, including limited donor cornea availability, risk of graft rejection, surgical complications, and substantial healthcare costs. Symptomatic management with hypertonic saline solutions, bandage contact lenses, and lubricating eye drops provides temporary relief but fails to address the underlying endothelial cell dysfunction, highlighting the critical need for innovative therapeutic approaches.

Discover emerging trends in the bullous keratopathy treatment landscape @ Bullous Keratopathy Therapies Market.

The bullous keratopathy pipeline has shown promising advancement in recent years, with several innovative therapies in clinical development. Aurion Biotechnologies (NYSE: AURN) has emerged as a pioneer with VYZNOVA, a cell therapy product launched in Japan in September 2024, which represents a significant step forward in treating bullous keratopathy. Emmecell is progressing with EO2002, completing the final dose administration for the last patient in its US Phase I trial in April 2024, with a Phase III pivotal study scheduled for the first quarter of 2025. Additional promising candidates include TTHX1114 (NM141) by Trefoil Therapeutics and CLS001 by Cellusion, which aim to either regenerate corneal endothelial cells or provide novel mechanisms to address corneal edema and bullae formation.

Unlock which bullous keratopathy emerging therapy is expected to capture the largest market share in 7MM by 2034. Visit the Bullous Keratopathy Market Insights.

Recent developments in the bullous keratopathy clinical trials landscape have generated significant optimism. In January 2025, preliminary results from a Phase II study of a novel Rho-kinase inhibitor demonstrated substantial improvement in corneal clarity and thickness in patients with moderate bullous keratopathy, suggesting potential as a non-surgical intervention. Additionally, early data from a corneal endothelial cell expansion technology being developed through a collaboration between academic research institutions and industry partners has shown promising results in ex vivo studies, potentially offering a solution to donor tissue shortages for transplantation procedures.

Despite these advancements, significant challenges remain in the bullous keratopathy treatment market. Limited disease awareness among primary care physicians and general ophthalmologists can lead to delayed diagnosis and intervention. The complex nature of corneal endothelial cell biology presents hurdles for developing targeted pharmacological approaches, while high treatment costs and limited reimbursement pathways create access barriers, particularly for innovative cell therapies. DelveInsight's analysis emphasizes that addressing these challenges will require coordinated efforts among healthcare stakeholders, including enhanced physician education, streamlined regulatory pathways for cell-based therapies, and the adoption of value-based reimbursement models.

Looking ahead, the bullous keratopathy market is poised for transformation through the advancement of cellular therapies, targeted pharmacological agents, and tissue engineering approaches. The integration of artificial intelligence in diagnosing and monitoring disease progression is expected to enhance treatment planning and outcomes assessment. Additionally, combination therapies targeting multiple aspects of corneal endothelial dysfunction may provide more comprehensive and durable benefits than current single-modality approaches. With increasing investment in research and development, along with a greater focus on this previously underserved condition, patients with bullous keratopathy can expect expanded treatment options and an improved quality of life in the coming decade.

Table of Contents

1. Key Insights

2. Report Introduction

3. Bullous Keratopathy Market Overview at a Glance

4. Methodology of Bullous Keratopathy Epidemiology and Market

5. Executive Summary of Bullous Keratopathy

6. Key Events

7. Bullous Keratopathy Background and Overview

8. Bullous Keratopathy Patient Journey

9. Bullous Keratopathy Epidemiology and Patient Population

10. Bullous Keratopathy Marketed Drugs

11. Bullous Keratopathy Emerging Drugs

12. Bullous keratopathy: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT

15. Bullous Keratopathy Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight